|Day's Range||48.67 - 50.75|
|52 Week Range||37.35 - 55.38|
|PE Ratio (TTM)||-21.18|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
Q1 2017 Neurocrine Biosciences Inc Earnings Call
Patients on the recommended dose will pay double — about $5,300 more a month.
Bayer Aktiengesellschaft (BAYRY) announced that it has enrolled the first patient in a phase III study ASTEROID which will evaluate vilaprisan in women suffering from uterine fibroids.